Latest News

  • First CAR T-cell gene therapy approved in the USA

    On August 30,2017, the US Food and Drug Administration (FDA) made the first gene therapy available in the United States: They approved Kymriah, a cell-based gene therapy, for the treatment of patients up to the age of 25 with acute lymphoblastic leukemia (ALL). The CAR T-cells potential has been detected already 20 years ago and research in the...
  • Successes and challenges of leukaemia treatment using CAR-T cells – where are we now?

    Treatment of leukaemia and lymphomas using genetically modified immune cells of the patient (CAR-T cells) has produced impressive results in clinical trials, especially for the treatment of B-cell malignancies. However, serious adverse events were reported as well, partly with fatal outcome. A detailed summary of previously published results and a...
  • Deadline for CARAT training course on CAR T cell manufacturing extended!

    The EU project CARAT has taken on the mission to deliver new tools and technologies to enable the wide use of novel personalized cancer treatment options. In 2017, CARAT will grant five scientists with a fellowship that gives them the opportunity to participate in a unique training. This training, which is coordinated by Miltenyi Biotec, has the...
  • ESB2017 Conference

    Last Call for abstracts
  • CARAT offers fellowships for a training course on CAR T cell manufacturing

    The EU project CARAT has taken on the mission to deliver new tools and technologies to enable the wide use of novel personalized cancer treatment options. In 2017, CARAT will grant five scientists with a fellowship that gives them the opportunity to participate in a unique training. This training, which is coordinated by Miltenyi Biotec, has the...
  • CARAT consortium getting together for their 1st CARAT Progress Meeting

    Nine months into the project and with the 1st project interim report around the corner, the CARAT consortium gathered together on September 29-30, 2016 for their 1st Progress Meeting. The meeting was hosted by CARAT’s partner Ospedale San Raffaele (OSR) in Milan, Italy, the perfect location to discuss the way forward motivated by some last late...
  • Licence to kill – the enormous potential of CAR T cells

    With 6 million euros of EU funding, the CARAT project aims to optimise a technology called CAR T that is used to equip T cells with antibody fragments and specifically direct them to destroy cancer cells. The CARAT consortium comprises a multinational team of experts from the Institute for Cell- and Gene Therapy at the Freiburg University Medical...
  • High yield at high selectivity – lentiviral vectors with Nipah envelope proteins developed

    Langen, 09.06.2016. To transfer genes exclusively into the patient’s therapy relevant cells is in the focus of current research approaches in gene therapy. Researchers of the Paul-Ehrlich-Institut have succeeded in modifying envelope proteins of Nipah virus (NiV) and to combine them with lentiviruses in such a way that they can now be used for a...

Upcoming Events